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Safety and efficacy of digoxin: systematic review and  
meta-analysis of observational and controlled trial data
Oliver J Ziff,1,2 Deirdre A Lane,1,3 Monica Samra,2 Michael Griffith,4 Paulus Kirchhof,1,3 
Gregory Y H Lip,1,3 Richard P Steeds,4 Jonathan Townend,1,4 Dipak Kotecha1,3,4,5 
ABSTRACT
ObjeCtive
To clarify the impact of digoxin on death and clinical 
outcomes across all observational and randomised 
controlled trials, accounting for study designs and 
methods.
Data sOurCes anD stuDy seleCtiOn
Comprehensive literature search of Medline, Embase, 
the Cochrane Library, reference lists, and ongoing 
studies according to a prospectively registered design 
(PROSPERO: CRD42014010783), including all studies 
published from 1960 to July 2014 that examined 
treatment with digoxin compared with control (placebo 
or no treatment).
Data extraCtiOn anD synthesis
Unadjusted and adjusted data pooled according to 
study design, analysis method, and risk of bias.
Main OutCOMe Measures
Primary outcome (all cause mortality) and secondary 
outcomes (including admission to hospital) were 
meta-analysed with random effects modelling.
results
52 studies were systematically reviewed, comprising 
621 845 patients. Digoxin users were 2.4 years older 
than control (weighted difference 95% confidence 
interval 1.3 to 3.6), with lower ejection fraction (33% v 
42%), more diabetes, and greater use of diuretics and 
anti-arrhythmic drugs. Meta-analysis included 75 study 
analyses, with a combined total of 4 006 210 patient 
years of follow-up. Compared with control, the pooled 
risk ratio for death with digoxin was 1.76 in unadjusted 
analyses (1.57 to 1.97), 1.61 in adjusted analyses (1.31 
to 1.97), 1.18 in propensity matched studies (1.09 to 
1.26), and 0.99 in randomised controlled trials (0.93 to 
1.05). Meta-regression confirmed that baseline 
differences between treatment groups had a 
significant impact on mortality associated with 
digoxin, including markers of heart failure severity 
such as use of diuretics (P=0.004). Studies with better 
methods and lower risk of bias were more likely to 
report a neutral association of digoxin with mortality 
(P<0.001). Across all study types, digoxin led to a small 
but significant reduction in all cause hospital 
admission (risk ratio 0.92, 0.89 to 0.95; P<0.001; 
n=29 525).
COnClusiOns 
Digoxin is associated with a neutral effect on mortality 
in randomised trials and a lower rate of admissions to 
hospital across all study types. Regardless of 
statistical analysis, prescription biases limit the value 
of observational data.
Introduction
Heart failure and atrial fibrillation are two emerging 
epidemics of the 21st century. Despite considerable 
advances in the management of both conditions, there 
remain controversies regarding some of the most widely 
used drugs, including β blockers1  and cardiac glyco-
sides.2  Digitalis, first introduced to clinical cardiology 
by William Withering in Birmingham around 1785, has 
widely been used as a positive inotrope in heart failure 
and for its negative chronotropic activity in atrial fibril-
lation. Recently, the use of digoxin has declined,3-5 par-
tially because of concerns about safety after the 
publication of observational studies reporting 
increased mortality with digoxin.6-8 In contrast, the 
largest randomised controlled trial of digoxin in heart 
failure (the DIG trial) showed neutral effects on mortal-
ity and a reduction in admissions to hospital compared 
with placebo, as well as a decrease in mortality among 
those with low serum digoxin concentrations.9 10 The 
results of several smaller randomised trials were consis-
tent with these findings, showing that digoxin improves 
symptoms and prevents clinical deterioration.11
In atrial fibrillation, however, no such experimental 
trials exist, and confusion about whether digoxin is truly 
linked to adverse prognosis has led to the downgrading 
of digoxin in clinical practice guidelines.12-14  Two recent 
meta-analyses have supported this view but were based 
solely on a small selection of observational studies,15 16 
highlighting the need for a more comprehensive assess-
ment. Furthermore, the finding that β blockers have no 
prognostic impact in patients with heart failure and con-
comitant atrial fibrillation1 has again led to questions as 
to what alternatives clinicians have available. There is 
therefore a clear imperative to define the place of digoxin 
in the clinical management of both heart failure and 
atrial fibrillation and to guide physicians and patients 
with an indication for treatment with digoxin.
WhAT IS AlReAdy knoWn on ThIS TopIC
Digoxin is often used to reduce symptoms in patients with heart failure, as well as 
to control heart rate in those with atrial fibrillation
Recent observational studies have suggested increased mortality associated with 
digoxin, but these are limited by prescription bias, as only those patients at highest 
risk tend to receive digoxin
WhAT ThIS STudy AddS
Our study comprehensively assessed data on mortality and cardiovascular 
outcomes from all studies since 1960 comparing the use of digoxin versus placebo 
or no treatment  
Using meta-analysis and meta-regression techniques, we have highlighted the 
importance of basing treatment decisions on randomised controlled trial data, 
rather than observational studies, which are unable to correct for inherent bias
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Digoxin is particularly prone to prescription bias as cli-
nicians have been trained to use digoxin in sicker 
patients. Statistical adjustment of observational data 
does not remove all confounding, and even techniques 
such as propensity score matching cannot replace ran-
domised allocation.17-19   Different types of adjustment for 
confounders often result in conflicting findings, adding to 
confusion for clinicians. For example, with the same 
dataset, three post hoc analyses of the Atrial Fibrillation 
Follow-up Investigation of Rhythm Management 
(AFFIRM) trial reported different conclusions regarding 
the safety of non-randomised prescriptions of digoxin.20- 22
In view of the potential usefulness of digoxin in heart 
failure and atrial fibrillation, and in an attempt to settle 
the uncertainty over adverse outcomes, we assessed the 
efficacy and safety of digoxin by comprehensively 
meta-analysing all available observational and experi-
mental studies. Our hypothesis was that study design 
would have an important impact on the observed mor-
tality associated with digoxin.
Methods
eligibility criteria and search strategy
We evaluated all studies that examined comparative out-
comes with digoxin and control (placebo or no treat-
ment), regardless of study design. All cardiovascular 
outcomes and all populations were included. We 
excluded studies that did not provide comparative out-
comes or were not published as full text articles in 
English. The definitions of heart failure, atrial fibrilla-
tion, coronary artery disease, and myocardial infarction 
used by each individual study were accepted. We system-
atically reviewed Medline (1960 to July 2014), Embase 
(1980 to July 2014), and the Cochrane Library (until July 
2014 Issue). The search strategy included keywords and 
MeSH terms relating to cardiac glycosides and death, 
admission to hospital, or other cardiovascular outcomes. 
We also manually searched reference lists of relevant 
studies, investigated registers of ongoing trials, and 
included studies after discussion with content experts.
The review was conducted according to the Preferred 
Reporting Items for Systematic reviews and Meta-Anal-
yses (PRISMA) guidelines.23  The project was prospec-
tively registered with the PROSPERO database of 
systematic reviews (CRD42014010783).24
Data collection, synthesis, and risk of bias
Two investigators (OJZ and MS) independently extracted 
and tabulated data on a standardised data extraction 
form. Discrepancies and missing data were resolved by 
group discussion, reference to the original publication, 
and additional independent adjudication (DK). All data 
were extracted from studies, including crude outcome 
data and adjusted analyses, comprising multivariate 
adjustment and propensity matched data, where avail-
able. Careful note was made of the analysis method 
(including risk ratio (preferred), odds ratio, or hazard 
ratio) and the population studied. Additional unpub-
lished data were provided from the authors of two  studies 
on clinical outcomes of interest .25 26  Studies by Freeman 
and colleagues27  and Whitbeck and colleagues20  were 
excluded from the quantitative meta-analysis as digoxin 
was assessed in a time dependent fashion, whereas all 
other studies assessed digoxin at baseline. Jorge and col-
leagues28  and Domanski and colleagues29  were not 
meta-analysed as crude event rates were not presented. 
Gheorghiade and colleagues21  and Whitbeck and col-
leagues20  provided unadjusted data derived from the 
same cohort (the AFFIRM trial), albeit with different 
patient inclusion. We performed a sensitivity analysis 
and inclusion/exclusion of one or the other study had no 
effect on results. Ancillary analyses of trials were not 
included if the original study reported mortality out-
comes for the whole population. When more than two 
treatment arms were assessed, we incorporated only the 
digoxin and placebo treatment effects.30 31  We also 
included two studies in press at the July 2014 cut-off date; 
both were subsequently published in full.7 8
We assessed the risk of bias with the Cochrane Col-
laboration’s risk of bias tool for randomised controlled 
trials and the risk of bias assessment tool for non-ran-
domised studies (RoBANS), both of which address key 
criteria such as selection bias, exposure measurement, 
blinding, completeness of outcome data, and selectivity 
of reporting.32 33 We assessed of risk of bias using these 
standardised tools independently from data extraction, 
with each study assessed by two authors and adjudica-
tion by a third when required.
Primary and secondary outcomes
The predefined primary outcome was all cause mortal-
ity. Secondary outcomes included cardiovascular 
 mortality; admission to hospital for any cause, cardio-
vascular causes, and heart failure; incident stroke; and 
incident myocardial infarction. We also explored evi-
dence for a dose related effect on outcomes.
statistical analysis
We meta-analysed baseline demographics, comparing 
the digoxin and control groups from all studies that pro-
vided unadjusted data, and summarised them as the 
weighted mean difference or odds ratio. Meta-analysis 
was prespecified to use a random effects model because 
of the anticipated variety in study designs and popula-
tions. Pooled binary event data for digoxin and control 
cohorts were compared with risk ratios and associated 
95% confidence intervals with the method of DerSimo-
nian and Laird.34  In cases where the odds ratio was 
described, we converted these to a risk ratio for 
meta-analysis (RR=OR/([1−pRef]+[pRef*OR]), where 
pRef is the prevalence of the outcome in the reference 
group).35 Results provided as hazard ratios were 
meta-analysed separately from risk ratios.
Outcomes were assessed according to type of analysis 
(unadjusted, adjusted, propensity matched, and ran-
domised controlled trials) and the population studied 
(heart failure and/or atrial fibrillation, or other popula-
tions including unspecified). Because of the small number 
of trials available for analysis of admission to hospital, we 
performed two exploratory meta-analyses that included 
various study types. We assessed these with a fixed effects 
approach according to the method of Mantel and 
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Haenszel,36 with confirmation using the random effects 
model previously described. Sensitivity analyses were per-
formed according to study design and by subpopulations, 
including a post hoc defined assessment in patients with 
concomitant heart failure and atrial fibrillation.
Heterogeneity was assessed with χ2 squared test and I2 
statistic, with the estimate of heterogeneity taken from 
the inverse variance fixed effects model. Meta-regression 
was performed to assess the impact of baseline variables 
on the logarithm of effect estimates of crude unadjusted 
mortality outcomes from observational data. The pri-
mary assessment used the residual maximum likelihood 
with random effects weighting and the Knapp and Har-
tung t-distribution.37  To avoid false positive results, we 
confirmed our findings using the method of moments, 
with P value calculation from 20 000 random Monte 
Carlo permutations.38 An exploratory meta-regression 
was performed according to the risk of bias attributed to 
each study. Publication bias was assessed with Begg’s 
test and Egger’s test to identify small study effects 
according to study analysis methods and also in the over-
all cohort disregarding study design. A two tailed P=0.05 
was considered significant. Analyses were performed 
with Stata Version 13.1 (StataCorp LP, TX).
Results
The search strategy identified 52 studies for systematic 
review, including 621 845 patients allocated to digoxin 
treatment or control, representing 2 248 775 patient 
years of follow-up (fig 1).  Overall, 144 593 patients were 
taking digoxin (23.3%) compared with 476 984 in the 
control arms (76.7%). Study descriptors are summarised 
in table A in appendix 1. Of the 42 studies, 26 were retro-
spective or prospective cohorts,6 7 25 28 39-59 nine were post 
hoc analyses of randomised trials,20 21 60-66 and seven 
were randomised on the basis of digoxin.9 30 31 67-70 The 
length of follow-up (weighted average) was 3.7 (SD 2.4) 
years with a range of 0.25-8.2 years.
Table 1 summarises the differences in key character-
istics between digoxin and control groups (for full base-
line demographics, see table B in appendix 1). Patients 
receiving digoxin were older than controls (weighted 
mean difference 2.4 years), more likely to be diabetic, 
and more often receiving diuretics or anti-arrhythmic 
drugs. Sample size weighting suggested that mean left 
ventricular ejection fraction was lower in digoxin 
patients (0.33) than controls (0.42). We were unable to 
meta-analyse left ventricular ejection fraction because 
of a lack of data on standard deviation.
The risk of bias in individual studies is presented in 
tables C and D in appendix 1. As expected, this was pro-
portional to the robustness of study design, with ran-
domised controlled trials having the lowest risk of bias. 
There was no evidence of small study effects or publica-
tion bias in any of the analysis groups individually or 
when we combined all studies using the most adjusted 
analysis available (all P>0.1 for Begg’s and Egger’s tests).
Meta-analysis was suitable for five outcomes: all 
cause mortality, cardiovascular mortality, all cause hos-
pital admissions, cardiovascular hospital admissions, 
and heart failure hospital admissions.
all cause mortality
Forty one studies were suitable for meta-analysis of 
all cause mortality.6-9 20 21 25 26 30 31 39 40-53 55 56-70 These 
studies contributed to 75 separate analyses, with an 
overall combined total of 999 994 patients and 
4 006 210 patient years of follow-up across four anal-
ysis subtypes (table 2 ). Figure 2 presents a summary 
of the individual meta-analyses performed. We per-
formed an exploratory meta-regression of the effect 
of study level bias on all cause mortality for digoxin 
compared with control. This analysis confirmed that 
studies with higher bias reported a greater associa-
tion of digoxin with death (P<0.001; fig 3  and table 3). 
Appendix 2 shows results of studies not included in 
the meta-analysis.
Studies included in quantitative sythesis
of outcomes (meta-analysis) (n=42)*
Titles and abstracts screened (n=1916)
Full text articles assessed for eligibility (n=1916)
Studies included in qualitative synthesis (n=52)
Extra records identi ed
through other sources (n=34)
Records identi ed through
database searching (n=1882)
Records excluded (n=1834)
Full text articles excluded (n=30):
  No mortality data (n=19)
  Duplicate patients (n=11)
Articles excluded (n=10):
  No crude data (n=2)
  Time varying exposure (n=2)
  Dose study (n=6)
Analyses (n=75):
  Unadjusted (n=33)
  Adjusted (n=22)
Propensity matched (n=13)
Randomised (n=7)
Fig 1 | selection of studies flowchart (after duplicates 
removed) on safety and efficacy of digoxin. *Primary 
outcome (all cause mortality) includes data from 41 
studies
table 1 | Pooled weighted characteristics of baseline 
demographics in patients treated with digoxin compared 
with control. Figures are odds ratio (95% Ci) unless 
stated otherwise
baseline 
characteristic
Digoxin v control arm  
(95% Ci) P value
Age (years) 2.47* (1.36 to 3.57) <0.001
Men 0.90 (0.81 to 1.00) 0.063
Diabetes 1.38 (1.21 to 1.57) <0.001
Atrial fibrillation 4.35 (2.73 to 6.93) <0.001
Heart failure 4.22 (2.85 to 6.23) <0.001
Diuretic 3.22 (2.21 to 4.68) <0.001
β blocker 0.75 (0.61 to 0.92) 0.005
Anti-arrhythmic 1.66 (1.08 to 2.56) 0.021
*Weighted mean difference.
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Unadjusted data from observational studies
Unadjusted mortality rates for digoxin and control 
were  available in 33 observational analyses 
(n=331 935).6-8  20 21 25 26 39 40-66 The risk ratio for all cause mor-
tality was 1.76 (95% confidence interval 1.57 to 1.97; 
P<0.001; fig A in appendix 3). There was substantial het-
erogeneity across trials (>90%; P=0.001). In studies per-
taining only to heart failure and/or atrial fibrillation 
cohorts, the risk ratio was 1.33 (1.19 to 1.50; P<0.001) com-
pared with 2.61 (2.12 to 3.22; P<0.001) for other patient pop-
ulations. In 28 studies that provided crude event numbers, 
18 161/69 763 (26.0%) patients died in the digoxin group 
compared with 37 563/200 266 (18.8%) in the control arm.
Meta-regression was used to explore the impact of 
differences in key baseline characteristics between 
digoxin and control patients on all cause mortality in 
observational data. Studies with smaller differences in 
the percentage of patients with diabetes, as well as 
those receiving diuretics and anti-arrhythmic drugs, 
reported less difference in mortality between digoxin 
and control. At study level, baseline age and year of 
publication also significantly affected the comparative 
risk of death between patients treated with digoxin and 
control (table 3 and fig B in appendix 3).
Adjusted data from observational studies
Adjusted mortality data were available for 22 observa-
tional analyses (n=245 049).7 21 26 41-45 47 50 53 55-59 62 63 65 66 Com-
pared with control, digoxin was associated with an 
increased risk of death (risk ratio 1.61, 95% confidence 
interval 1.31 to 1.97, P<0.001; hazard ratio 1.17, 1.07 to 1.29, 
P=0.001; see fig C in appendix 3). In studies that enrolled 
only patients with heart failure and/or atrial fibrillation, 
the risk of death associated with digoxin use was of bor-
derline significance (hazard ratio 1.16, 1.05 to 1.28; P=0.04). 
Adjustment factors varied widely (table E in appendix 1).
Propensity matched observational studies
Thirteen analyses (n=414 604) used a propensity 
matched cohort design.6-8 21 46 48 56-58 67 Compared with 
control, digoxin use was associated with a small 
increased risk of death in studies that reported risk ratio 
(1.18, 95% confidence interval 1.09 to 1.26; P<0.001). 
There was no significant association in studies that 
reported hazard ratios (1.07, 0.96 to 1.19; P=0.20; fig D in 
appendix 3). In studies of patients with heart failure 
and/or atrial fibrillation, there were similar results for 
risk ratios (1.18, 1.10 to 1.27; P<0.001), but no difference 
in mortality for studies reporting hazard ratios (1.00, 
0.84 to 1.20; P=0.99).
table 2 | summary of studies and patients in systematic review and meta-analyses of safety and efficacy of digoxin 
Outcome and analysis no of studies no of analyses Digoxin patients Control patients
total no of 
patients
Patient years of 
follow-up
Systematic review 52 — 144 593* 476 984* 621 845 2 248 775
All cause mortality:
 Unadjusted observational 29 33 91 606 240 329 331 935 1 166 223
 Adjusted observational 20 22 67 649 177 400 245 049 1 009 208
 Propensity matched 10 13 96 877 317 727 414 604 1 806 405
 Randomised 7 7 4203 4 203 8406 24 373
 Total combined 41 75 260 335 739 659 999 994 4 006 210
All cause mortality in heart failure plus 
atrial fibrillation
4 6 22 344 23 930 46 274 139 769
Cardiovascular mortality:
 Observational 3 3 1300 10 099 11 399 53 511
 Randomised 5 5 4037 4031 8 068 24 240
    Total combined 8 8 5337 14 130 19 467 77 751
All cause hospital admission:
 Unadjusted observational 2 2 3023 12 130 15 153 65 965
 Propensity matched 4 4 3598 2986 6584 17 218
 Randomised 2 2 3889 3899 7788 24 143
 Total combined 8 8 10 510 19 015 29 525 107 325
Heart failure hospital admission 6 6 9701 7977 17 678 60 869
Cardiovascular hospital admission 3 3 4101 4222 8 323 25 694
Incident myocardial infarction 3 3 7800 7317 15 117 41 732
Incident stroke 4 4 4962 27 938 32 900 106 172
Serum digoxin concentration 16 10 30 810 159 546 193 247 715 783
*Excludes study by Jorge and colleagues28 as separate numbers not provided.
Observational studies
  Unadjusted relative risk (n=33)
  
  Adjusted relative risk (n=8)
  Adjusted hazard ratio (n=14)
  Propensity matched relative risk (n=6)
  Propensity matched hazard ratio (n=7)
Randomised controlled trials relative risk (n=7)
1.76 (1.57 to 1.97)
1.61 (1.31 to 1.97)
1.17 (1.07 to 1.29)
1.18 (1.09 to 1.26)
1.07 (0.96 to 1.19)
0.99 (0.93 to 1.05)
0.5 1 2
Risk ratio/hazard
ratio (95% CI)
Risk ratio/hazard
ratio (95% CI)
Lower mortality
with digoxin
Higher mortality
with digoxin
Fig 2 | summary of meta-analyses for all cause mortality in observational and randomised 
studies on safety and efficacy of digoxin, comprising 999 994 participants across 75 study 
analyses. (see fig 4 and figs a, C, D, and e in appendix 3 for study level results)
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Randomised controlled trials
Seven randomised controlled trials were included 
(n=8406).9 30 31 67-70 There were no differences in mortality 
between patients randomised to digoxin or placebo (risk 
ratio 0.99, 95% confidence interval 0.93 to 1.05; P=0.75; 
fig 4). All seven of these trials were conducted in patients 
with heart failure. Importantly, there was no evidence of 
heterogeneity across studies (I2=0%, P=0.97).
all cause mortality in patients with heart failure and 
atrial fibrillation
We performed a post hoc defined sensitivity analysis to 
assess the impact of digoxin on mortality in patients 
with combined heart failure and atrial fibrillation, 
which included two analyses of crude observational 
data,46  55  two adjusted observational analyses,55  59  and 
two propensity matched cohorts8  46 (total n=46 274; 
139 769 patient years of follow-up). Digoxin had no sig-
nificant effect on mortality in this patient group (see fig 
E in appendix 3). These studies included patients with a 
clinical heart failure syndrome, although on the basis of 
average left ventricular ejection fraction, most patients 
had heart failure with reduced ejection fraction.
Cardiovascular mortality
Limited data were available for cardiovascular mortality. 
In patients with heart failure and/or atrial fibrillation, 
five randomised studies (n=8068) found no association 
between use of digoxin and cardiovascular death (risk ratio 
1.01, 95% confidence interval 0.94 to 1.08; P=0.82).9 31 67 69 70 
In contrast, pooled data from one adjusted and two unad-
justed observational studies in other patient populations 
(n=11 399) found an increased risk of cardiovascular death 
(2.53, 1.12 to 5.71; P=0.025).39  45  63
admission to hospital, other cardiovascular events, 
and digoxin dose
Detailed results on admissions to hospital and other out-
comes are presented in appendix 2. To summarise, 
digoxin was associated with a small but significant 
reduction in all cause admission to hospital across all 
study types (overall risk ratio 0.92, 95% confidence inter-
val 0.89 to 0.95; P<0.001; fig F in appendix 3), as well as 
significantly lower rates of admissions related to cardio-
vascular disease and heart failure (see fig G in appendix 3). 
There was no evidence for any increase or reduction in 
other cardiovascular events with digoxin, such as myo-
cardial infarction or incident stroke. Limited information 
on digoxin dose suggests that lower serum digoxin con-
centrations of between 0.5 and 0.9 ng/mL were associ-
ated with improved prognosis, whereas higher 
concentrations correlated with increased mortality.
discussion
Digoxin has a neutral effect on all cause mortality in ran-
domised trials and is associated with a reduction in hos-
pital admission. This finding is based on a comprehensive 
systematic review including over 600 000 patients, with 
meta-analysis incorporating a combined total of four mil-
lion patient years of follow-up. Based on our analysis, 
observational studies that report increased mortality 
with digoxin use (regardless of statistical methods) were 
unable to adjust for systematic differences in the type of 
patients who received digoxin. Uniquely, we were able to 
show that studies exhibiting a higher risk of bias reported 
a stronger association with all cause mortality, highlight-
ing the need to base clinical decisions relating to patient 
management on high quality data derived from con-
trolled trials, rather than post hoc or observational data.
Heart failure and atrial fibrillation cause a substantial 
burden of disease worldwide.71 72  Throughout most of 
the past century, digoxin was routinely used to improve 
cardiac output and to avoid admission to hospital. 
Based on information from large randomised trials, the 
use of digoxin has been eclipsed by the widespread ini-
tiation of drugs with prognostic benefit, including ACE 
inhibitors73 , β blockers (in sinus rhythm),1  and aldoste-
rone antagonists.74 75  This decline in use followed evi-
dence from the DIG Trial that digoxin does not reduce 
Risk of bias summary score
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Fig 3 | Meta-regression of all cause mortality according to 
risk of bias and efficacy of digoxin. risk of bias in each study 
was summed across all six domains (low risk=0, unclear 
risk=1, high risk=2; excluding “other threats to validity” 
domain from Cochrane risk of bias tool). all analyses that 
provided data on rates of death were included, regardless of 
study design. each circle represents particular study, with 
circle size dependent on precision of each estimate in 
random-effects model (inverse of its variance)
table 3 | Meta-regression for all cause mortality in studies on safety and efficacy of 
digoxin
risk of bias assessment (all 
studies)
no of 
analyses
regression equation β 
coefficient (95% Ci)*
P value†
Method 1 Method 2
Summary bias score (per 1 point) 61 1.09 (1.05 to 1.12) <0.001 <0.001
Difference between digoxin and control arms at baseline (observational studies)
Diabetes (per 10% difference) 21 1.58 (1.14 to 2.19) 0.008 0.005
Hypertension (per 10% difference) 15 1.23 (0.88 to 1.73) 0.201 0.272
Diuretics (per 10% difference) 14 1.19 (1.07 to 1.33) 0.004 <0.001
Anti-arrhythmic drugs (per 10% 
difference)
7 1.69 (1.22 to 2.34) 0.009 0.030
baseline study level variable (observational studies)
Year of publication (per 5 years) 28 0.88 (0.83 to 0.93) <0.001 0.001
Age (per 10 years) 22 0.72 (0.60 to 0.87) 0.001 0.002
Male sex (per 10%) 22 1.11 (0.99 to 1.26) 0.075 0.117
Previous myocardial infarction  
(per 10%)
17 1.10 (1.01 to 1.20) 0.028 0.043
*β coefficient for natural logarithm of effect size for each variable of interest reflecting unit change (for example, 
per 1 point change in summary bias score (range 0-12) or per 10% difference between digoxin and control arms).
†See figure 3 and fig B in appendix 3. Primary assessment used residual maximum likelihood with random effects 
weighting and Knapp and Hartung t-distribution (method 1). To avoid false positive results, we confirmed our 
findings using method of moments, with P value calculation from 20 000 random Monte Carlo permutations 
(method 2).
doi1 21.22;6/bmj.hhh02 | BMJ   2105;021hhh02 | the bmj
RESEARCH
6
mortality in patients with heart failure,9  despite high 
rates of concomitant digoxin use in most trials of treat-
ment for heart failure. Currently, European and Ameri-
can guidelines recommend digoxin for persistent 
symptoms, despite optimal treatment, or as an alterna-
tive/adjunct to reduce hospital admissions.76 77  Atrial 
fibrillation guidelines preferentially suggest treatment 
with β blockers over digoxin, except in sedentary 
patients or as an adjunct for additional rate control.13 78
Heart failure and atrial fibrillation often co-exist, lead-
ing to further adverse prognosis.79-81  A recent individual 
patient data meta-analysis showed that β blockers had 
no significant effect on mortality or hospital admission in 
patients with heart failure and reduced ejection fraction 
and concomitant atrial fibrillation.1  In this context, cli-
nicians have only a single other choice of rate control 
treatment—namely, digoxin—as calcium channel block-
ers can have negatively inotropic effects in failing 
hearts.82 83  In this increasingly prevalent population, our 
findings regarding digoxin might be of particular clinical 
importance. Our analysis confirmed that, similar to β 
blockers, digoxin has a neutral effect on mortality in 
patients with co-existing heart failure and atrial fibrilla-
tion, even in observational studies with associated pre-
scription biases. Although there were insufficient data to 
assess hospital admissions specifically in patients with 
heart failure plus atrial fibrillation, we found that digoxin 
reduced admissions for any cause, cardiovascular 
causes, and heart failure across all study types. Whether 
digoxin has other beneficial effects, such as an increase 
in left ventricular ejection fraction or improvement in 
quality of life, has yet to be determined in patients with 
atrial fibrillation (for example, the proposed RAte control 
Therapy Evaluation in Atrial Fibrillation [RATE-AF] ran-
domised trial84 ). This type of information is vital if we are 
to defend against the enormous healthcare burden posed 
by these two conditions.85 86
As digoxin is no longer first line treatment for either 
atrial fibrillation or heart failure, it is often prescribed 
when clinicians detect deterioration in patients resis-
tant to initial treatment. Thus, treatment with digoxin is 
likely to be influenced by the probability of mortality, 
creating a scenario of “confounding by indication.”87 
We have clearly shown the profound differences in 
baseline characteristics between patients in digoxin 
and control groups in observational studies and 
exposed their impact on all cause mortality through 
meta-regression methods. These differences could 
partly explain the conflicting results from recent obser-
vational studies derived from similar cohorts,20 21 22  a 
problem not unique to cardiology trials.88 89  The dispar-
ity in these studies promotes the notion that even 
sophisticated statistical methods should be interpreted 
with caution and cannot replace randomisation. 
Although statistical adjustment for known confounders 
is often used to combat allocation bias (for example, 
with propensity matching), important confounders can 
be unknown or masked. Even with a reasonable selec-
tion of adjustment variables, when treatment and con-
trol groups differ vastly in characteristics, reliable effect 
estimates are not possible without breaching the 
assumptions of the statistical model.90 91 92 With regards 
to digoxin, our analysis shows that adjustment for 
known confounders mitigates bias to an extent but will 
leave residual confounding that results in important 
clinical impact. Although digoxin has a higher ten-
dency to such bias than other treatments, the same 
principle will apply to other cardiovascular treatments, 
providing a cautionary reminder that observational 
data are hypothesis generating, rather than definitive.
Several additional studies in patients with atrial 
fibrillation were published during the analysis stage of 
our study, and these are highlighted in table F in appen-
dix 1. All were either post hoc assessments of trials or 
cohort/registry studies.93-99  One study found a lower 
death rate in patients treated with digoxin, three identi-
fied no association, and four identified higher mortality 
in patients treated with digoxin. In all studies there 
were substantial differences in the patients receiving 
digoxin compared with those receiving control treat-
ment, including higher rates of heart failure, more 
advanced atrial fibrillation, prognostically worse base-
line demographics, and receipt of drugs that have previ-
ously been associated with increased mortality, 
including anti-arrhythmic drugs. Taking all studies into 
account, our systematic review suggests that digoxin 
should continue to be considered as a treatment option 
to achieve control of heart rate in those with atrial fibril-
lation and also to avoid hospital admissions in patients 
with heart failure (fig 5). Despite our reassuring data 
with respect to mortality, clinicians should adhere to 
guidelines—for example, by ensuring the use of recom-
mended drugs and devices in patients with heart failure 
and reduced ejection fraction, and appropriate antico-
agulation in those with atrial fibrillation.
limitations
Our review is based on reported results of independent 
published studies, prepared according to explicit repro-
ducible methods. Although meta-analysis of individual 
patient data is the ideal,100 it is practically unfeasible 
with such large combinations of data across an extensive 
number of studies. We acknowledge several limitations 
of our analysis. Firstly, there is a clear and understand-
able discrepancy in the sample sizes from randomised 
and observational data. Secondly, both heart failure and 
1.22 (0.42 to 3.49)
0.34 (0.01 to 8.27)
0.79 (0.17 to 3.75)
0.32 (0.01 to 7.63)
0.64 (0.11 to 3.69)
0.99 (0.93 to 1.06)
1.00 (0.80 to 1.25)
0.99 (0.93 to 1.05)
0.25 1 4
Random eects
risk ratio (95% CI)
Random eects
risk ratio (95% CI)
  Captopril-Dig Group, 198830
  Xamoterol Study Group, 198868
  DiBianco, 198931
  Blackwood, 199069
  Van Veldhuisen, 199370
  DIG Trial, 19979
  Ahmed, 200667
Overall risk ratio: P=0.95
Hetergeniety: P=0.97, I2=0%
Study
0.5 2
Higher mortality
with control
Higher mortality
with digoxin
Fig 4 | Meta-analyses of all cause mortality in randomised controlled trials on safety and 
efficacy of digoxin
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atrial fibrillation have a wide clinical spectrum, from 
asymptomatic disease to a severe uncontrolled condi-
tion. Definitions of heart failure and atrial fibrillation in 
different studies varied, and we cannot exclude misclas-
sification. Although some studies reported the stage of 
heart failure, left ventricular  ejection fraction, and the 
type of atrial fibrillation, many studies did not.
Thirdly, because of anticipated differences in study 
design and populations, we prespecified a random 
effects model. Although we noted substantial heteroge-
neity for all cause mortality between observational tri-
als, this was not evident in meta-analysis of randomised 
controlled trails. We were unable to perform meta-anal-
ysis of serum digoxin concentration, digoxin dose, or the 
type of cardiac glycoside prescription (digoxin, digitalis, 
or digitoxin) because of insufficient data in the included 
studies. Of note, a large placebo controlled randomised 
trial has recently started recruitment, examining the 
effect of digitoxin in patients with heart failure and 
reduced ejection fraction.101  Although we found no evi-
dence of publication bias, statistical measurements can 
be misleading especially when heterogeneity is high.102
Finally, because of a lack of randomised data in 
patients with atrial fibrillation without heart failure, we 
are unable to comment on the prognostic impact of 
digoxin specifically in these patients. Observational 
data here are limited as between 30% and 50% of 
patients with atrial fibrillation also have heart failure,79 
and heart failure with preserved ejection fraction in par-
ticular is underdiagnosed.103 Although we saw no 
increase in mortality in patients with a clinical diagnosis 
of heart failure and concomitant atrial fibrillation, fur-
ther randomised data are awaited in patients with atrial 
fibrillation to settle this important clinical question.
Conclusion
Digoxin use has a neutral effect on mortality in ran-
domised trials and reduces hospital admissions. The 
association between digoxin and adverse outcomes in 
observational studies is likely to be non-causative and a 
result of confounding that cannot be mitigated by sta-
tistical adjustment. Future randomised trials of digoxin 
are urgently required to identify the place of this treat-
ment in the management of patients with heart failure 
and those with atrial fibrillation.
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